Life Sciences Archive » April, 2016

Life Sciences - April, 2016

339 articles

• Gilead OK'd To Show Merck Atty Lied In $200M Patent Win
• J&J Baby Powder Cancer Suit Goes To Missouri Jury
• Drug Firms Battle In Del., Calif. Over Shared LLC, $60M IP
• Pfizer Still Can't Compare Children's Advil To Tylenol In Ads
• NuVasive Can't Erase $28M Verdict, Former Distributor Says
• GSK Seeks To Ax Heart Attack Suit In Diabetes Drug MDL
• Cubicin Patent Axing Doesn't Warrant Review, Justices Told
• OPINION: Engaging The Media May Help Your Client
• ITC Finds Imported Dental Implants Flouted Nobel Patents
• 4 Firms Set To Launch Biotech IPOs That Could Raise $185M
• Pharma CEO Hid FDA Hold From Investors, Jury Finds
• Hollister, Byram To Pay $21M In FCA Kickbacks Case
• After Rejection, Sanofi Threatens Hostile Bid For Medivation
• Brand Battles: Dentons, J&J, University of Texas
• Deals Rumor Mill: Yahoo, Pfizer, Atlante
• Reckitt Must Pay $1.3M For Putting Different Labels On Drug
• Taxation With Representation: Baker & McKenzie, Gibson Dunn
• FDA Greenlights Quest Diagnostics' Zika Test
• Merck Defeats NJ Town's Bid To Check Land Development
• Colo. Credit Union Says KC Fed Can't Enforce Pot Laws
• Mylan, Ranbaxy Push 3rd Circ. To Nix Provigil Class
• FDA To Mull Mandatory Opioid Education For Prescribers
• Alere Refuses Abbott Bid To Back Out Of $5.8B Merger
• Portfolios With 4 Legs To Stand On: Animal Drug Patent Tips
• High Court May Be Next Stop For PTAB Deference Issue
• Pharma CEO Says He's An Honest Guy As SEC Trial Wraps
• Abbott's Cardio-Focused $25B Deal Could Raise FTC's Pulse
• Pharmacies Say Express Scripts Conspiracy Suit Has Legs
• KaloBios Gets Final Nod On 'Unusual' $3M Ch. 11 Package
• FDA Flouting Court On Orphan Drug Exclusivity, Suit Says
• 3 Big Plays Make Noise In Muted Health Care M&A Market
• Old Spice Deodorant Causes Rashes, Class Action Claims
• Merck Says Gilead Is Exploiting Atty 'Lie' In $200M Jury Loss
• Sanofi Leans On Biopharm Firm Medivation To Take $9.3B Bid
• AbbVie Inks $5.8B Deal For Cancer Drug Maker Stemcentrx
• Using The New Federal Rules To Rein In Discovery
• Why Celebrity Sponsors Aren't Liable For False Advertising
• Dentons: A New Kind Of Network?
• Wachtell Steers Abbott In $25B Deal For St. Jude Medical
• 22 Firms Win Top Marks From GCs On AFAs
• Crede Blasts Tobacco Co. In $250M Suit Over China JV
• Chancery Suit Targets Fee-Shifting Bylaw Enacted Before Ban
• IRS Inversion Regs Don't Solve Tax Code Issues, Rep. Says
• Valeant CEO Says He Was 'Too Aggressive' On Drug Prices
• Abbott Urges Judge To Keep RICO Claims In Test Strip Row
• Female Merck Workers Get Cert. In Sex Bias Suit
• Amgen Urges Ban On Cholesterol Drug Sales After Patent Win
• FTC Settles Monopoly Case With Medical Polymer Co. Invibio
• Fed. Circ. Won't Rehear Howmedica Polymer Patent Appeal
• 4th Circ. Affirms Toss Of Utah Woman's Vaginal Mesh Suit
• FDA Accused Of Hiding Details On Its Advisers
• Philly Paxil Litigation Paused During Fight Over Initial Case
• Amarin Again Dodges Securities Suit Over Vascepa Denial
• Olympus Expands Global Team With GC, Compliance Officer
• CVS Hits Back At Texas In 1st Circ. Medicaid Drug FCA Row
• What's The Big Deal About US Biosimilar Approval?
• 4th Circ. Revives FCA Suit Over Pfizer Pain Patch
• Lupin Wins Feds' OK Of Settlement In $850M Gavis Buy
• The Firms That Handle The Most ANDA Patent Cases
• Endo Loses DQ Bid In Consumer Suit Over Fluoride Labeling
• More Details Emerge Of Lab Practices At Theranos
• Fed. Circ. Keeps Deference For PTAB, Despite Misgivings
• Stryker Unit Slams DJO Over Worker Poaching Scheme
• FDA Mulls Study On Yeast Infection Drug's Miscarriage Risk
• Allergan, Others Hit With Generic Drug Price-Fixing Suit
• NY Insurers Agree To Provide Costly Hep C Treatments
• 1st Meningitis Bellwether Trial Pushed Back To August
• FDA Warning Wire: Drug Ratings Nixed By Suspect Tests
• Takeda, Blackfeet Member Ask 9th Circ. To Call Off Actos Suit
• What To Know About Trade Secret Law In Saudi Arabia
• Risk Of Future Misconduct Will Guide HHS Investigations
• Pfizer Accuses Lipitor Users Of Forum-Shopping In MDL
• Bard Ends Several Dozen Pelvic Mesh Suits In MDL
• GNC Slammed For 'Sham' Online Pricing Scheme
• 9th Circ. Won't Revive Wal-Mart Migraine Drug Price Suit
• Insurers, Hospitals Float Ideas To Curb Drug Spending
• Chiesa Shahinian Nabs 6 Herrick Feinstein LLP Attys
• Deals Rumor Mill: Novartis, Honeywell, KRG Capital
• Lowenstein Sandler Snags Ex-Mintz Levin Corporate Atty
• Biopharm Co. Says AstraZeneca Lifted Data, Seeks $33.8M
• IKOR Founder Seeks To Undo $5M Investment Breach Verdict
• Valeant Taps Perrigo CEO To Right Ship
• Quo Vadis FTC?: The Meaning Of FTC Case Against Endo
• The D&O Policy Implications Of SEC's Theranos Probe
• Pa. Justices Urged To Affirm $4.8M Asbestos Verdicts
• Health Hires: Akin Gump Gets A Fed, Morris Manning An IP Pro
• Jury Awards Concordia Pharma $730K In False Ad Row
• FDA Eyes Ban On Electric Shock For Violent Behavior
• Nixon Peabody Says Intel's Tapped Out In Biotech Stock Row
• First Mirena IUD Cases Dropped; Bayer Cites Lack of Experts
• Ex-Covidien Sales Manager Loses Age Bias Dispute
• Snooki, Diet Pill Co.'s False Ad Appeal Pointless, Group Says
• Benefits Of Expedited Review Of Sole-Source Drug ANDAs
• 4 Reasons Nonpharma Attys Should Know Pay-For-Delay Law
• Avoiding The Pitfalls Of Researching Attorneys In PACER
• Stock Tipper Can't Ax SEC Deal After Newman, 3rd Circ. Told
• FDA Rejects Surgical Robot From TransEnterix
• SEC Gets Injunction Against Ski Resort And CEO In EB-5 Suit
• Deals Rumor Mill: Vodafone, CMA CGM, Concordia Healthcare
• A Review Of Gov't Cases Against Execs In Q1
• PE-Backed American Renal Prices $165M IPO Near Peak Range
• IBio Settles Investor Suit Over Ebola Drug Plans For $1.87M
• FedEx Can't Duck Money Laundering Counts In Drug Case
• New Tax Plan Will Hurt IT, Pharma Vendors In Texas
• State Legislation Vs. Federal Prohibition Of Marijuana
• Dow Can't Pause Fed. Circ. Appeal Of $456M Bayer Award
• Sandoz Loses Bid To Invalidate IP In Toviaz Row With Pfizer
• Patents 'Decimated' By Eligibility Rulings, Justices Told
• Reckitt Ducks Drug Supply Order In Mucinex Antitrust Case
• Biotech Entrepreneur, Others Want OxyContin Case Reheard
• Drug Labels Must Reflect Risk Sooner, Tylenol Court Told
• 9th Circ. Vacates $2.3M Fee Award In Nobel Implant Row
• Del. Chief Justice Asks If 'Liars' Set Up $16M Stock Fault
• Supplement Buyers Push To Keep False Ad Class Action Alive
• Abbott CEO Silent On $5.8B Alere Deal Amid FCPA Scrutiny
• Pillsbury Nabs Ex-Sterne Kessler IP, Pharma Pro In DC
• Intuitive Cuts Deal Before Jury Verdict In $30M Robot Trial
• Resort Owner Says SEC Can Only Freeze $50M In EB-5 Suit
• IRS Says Colorado Pot Dispensary Can't Deduct Expenses
• Economics Of Harm From Biologic-Biosimilar Competition
• 2nd Circ.'s Application Of Janus Is Noteworthy
• SEC's Theranos Probe Shows Unicorn Hunt Not A Myth
• Express Scripts Countersues Anthem Amid $13B Suit
• Endo, Others Denied Wholesale Info In Pay-For-Delay MDL
• FDA Warning Wire: Coin Tosses, Raw Dog Food, Drug Gels
• Texas Slams CVS Stores In 1st Circ. Medicaid Drug Row
• FedEx Can't Dodge Prescription Drug Shipping Indictment
• J&J Loses Bids To Limit Testimony In Tylenol Bellwether
• GSK, Others Appeal UK Watchdog's Pay-For-Delay Penalties
• Celltrion Rips Janssen's Bid to Move Up Biosimilar Trial Date
• Apotex Says Mylan, Ranbaxy Rewrite Law In Provigil Appeal
• Mylan Says Fed. Circ. Jurisdiction Rule Unfair To Generic Cos.
• Immunosyn CEO Hid FDA Hold From Investors, Jury Told
• 3 Life Science Cos. Bolster IPO Pipeline With $101M In Deals
• Novartis Asks 3rd Circ. To Uphold Dismissal Of Zometa Suit
• Bellwether Trials: A Defense Perspective
• Interpreting A Patent Is Not So 'Plain And Ordinary' After All
• CytRx Using Forum Flip-Flop To Stall Del. Case, Investors Say
• Spending Bill Pushes FDA Approval Of Drug Label Changes
• Eli Lilly, Elan Get $8M In Fees After Alzheimer's IP Win
• Benicar MDL Cases Survive Daiichi's Symptom Challenges
• ConforMIS Investors Fight Bid To Toss Suit Over $140M IPO
• AstraZeneca, Ranbaxy Ask 1st Circ. To Affirm Nexium Win
• Theranos Under Investigation By SEC, US Attorney's Office
• Generics Group Decries 'Troubling' AbbVie Biosimilars Petition
• Wis. Tribe Pushes For Hemp Crop OK Over DEA Objections
• Deals Rumor Mill: AstraZeneca, Ardagh Group, Yahoo
• Drug Cos. Wants Chicago Opioid Suit Paused For FDA Results
• FTC, Supplement Co. Request Stay In False Ad Suit
• Investors Say KaloBios Doesn't Need $3M DIP Loan
• Littler Lures Jackson Lewis Employment Pro In Miami
• Another Take On Reed Smith, Pepper Hamilton Merger Talks
• Bristol-Myers Ruling Highlights Biologics Patent Eligibility
• The Best Law Firms For Female Partners
• The Glass Ceiling Report
• The Top 5 Ways BigLaw Is Failing Women
• The 100 Best Law Firms For Female Attorneys
• Sanofi Says Amgen Patents Doomed Despite Jury Win
• Ex-Morgan Stanley Exec's CPA Gets 1 Day For Trading Tips
• 7th Circ. Won't Revive IP Suit Over Amylin Drug Promos
• 3 Takeaways From FDA's Drug Compounding Guidances
• AbbVie Wants MedImmune's Humira Patent Invalidated
• Pom Ruling Controls Diet Drugs False Ad Claims: 9th Circ.
• Insurer Sues Over Defense Costs For Meningitis Suits
• Honigman Adds Simpson Thacher, Kirkland, Ropes Attys
• Takeda Slams FDA Approval Of Rival's Gout Drug At DC Circ.
• GenSight Pulls $65M IPO, 2nd Biotech To Do So This Week
• Pa. Judge Urged To Revive Paxil Case After Midtrial Ax
• Buyers Urge 3rd Circ. To Reopen Effexor Pay-For-Delay Suit
• AbbVie Retires Cholesterol Drugs Amid Risk-Benefit Doubts
• Deals Rumor Mill: MBK Partners, Gland Pharma, AC Milan
• Bristol-Myers Expands Bay Area Research Footprint
• 10 Things To Know About US Biosimilar Reimbursement
• J&J Unit Settles Ex-Exec's Whistleblower Claims In NJ
• OPINION: Advising The GOP About Its Obligation To Advise
• Proposed Theranos CEO Ban Ups Ante For Lab Testing Cos.
• Industry Outpaces Gov't Agencies On Cybersecurity: Report
• FDA Data Integrity Guide Ends Excuses For Suspect Records
• 3rd Circ. Urged To Reverse Ruling In Merck Fraud Row
• 11th Circ. Urged To Revive Med. Supplier's Malpractice Row
• S&P Lowers Valeant Credit Rating After Delayed SEC Filing
• PTAB Rejects AIA Challenge To Amgen Drug Patent
• SEC Accuses Ski Resort Owner, CEO Of $350M EB-5 Fraud
• Philly Cancer Center Says Licensee Broke Agreement
• China Retreats On Subsidies To Settle US WTO Case
• Trade Secret Pitfalls For The Hatch-Waxman Litigant
• IRS Settlement With Carmex Owners Is Surprising
• Walgreens Urges 3rd Circ. To Keep Provigil Class Certified
• Feds Float 2-Year Ban On Theranos CEO Holmes
• Health Care, Addiction Experts Want Opioid Rules Changed
• Biotech Co. Says Brewer's Kombucha Teas Infringe Its IP
• Deals Rumor Mill: Lonza Group, IDT, Deutsche Bank
• J&J Baby Powder Caused Ovarian Cancer, Jury Told
• Health Care-Focused PE Firm Surpasses $150M For New Fund
• Jury To Decide If J&J Fired Exec For Affair Or Whistlebowing
• Janssen Seeks Patent Trial To Halt Celltrion Biosimilar
• PTAB Can Institute AIA Reviews, USPTO Tells Fed. Circ.
• UK Fines Pfizer For Missed Deadline In Epilepsy Med Probe
• Prescription Drug Oversight Bill Headed To President
• Valeant CEO Will Testify About Drug Prices Before Senate
• Can The Life Sciences Industry Bank On Biosimilars?
• Trans Ova Gets Part Of Verdict Axed In Sex-Selection IP Row
• CVS Shoppers Ask 1st Circ. To Reverse Vitamin E Label Ruling
• Valeant Faces Default Amid Looming Debt
• FDA Panel Delays Approval Of Clovis' Lung Cancer Drug
• Valeant CEO Obstructing Drug Price Probe, Lawmaker Says
• Redskins Blast Government's Flanax Claim As 'Ironic'
• Health Cos. Settle FTC's 'All Natural' False Ad Claims
• House Agrees To Priority FDA Review For Zika Treatments
• Deals Rumor Mill: Chevron, Gryphon Investors, Tipico
• Parents Asks Justices To Up Standard In Vaccine Act Row
• VC-Backed Biotech, Midsize Bank Boost Growing IPO Pipeline
• Kappos Calls For Abolition Of Section 101 Of Patent Act
• Chinese Anti-Bribery Law May Be Changing
• FDA Warning Wire: Hospital In Mayo Clinic Network Scolded
• Fed. Circ. Affirms Nixing Of Bayer Contraceptive Patent
• How To Align APEC And EU Cross-Border Transfer Rules
• Forbion Capital Closes $208M Life Sciences Fund
• 2nd Circ. Revives Pfizer Securities Suit Over Drug Risks
• J&J Ultamet Verdict Is Too Much Green
• Hogan Lovells Adds Corporate Trio From Pepper Hamilton
• Boston Scientific Recalls Catheters Over Breakage Risk
• Diet Pill Co., Snooki Want 2nd Circ. Input In False Ad Suit
• Valeant Board Urges CEO To Show For Senate Deposition
• Bone Stimulator Co. Beats FCA Doc-Coaching Suit
• Man Asks 9th Circ. To Recertify 'Sexual Energy' False Ad Class
• NY Human Tissue Co. Escapes Body Parts Harvesting Suit
• Foley Hoag Nabs Capital Markets Pro From Locke Lord
• Wi-Fi Band Expansion May Harm Hearing Aids, FCC Warned
• GNC Agrees To Pay $9M To End Calif. Labor, Wage Class Suit
• Label Suit Should Be Erased, Drugmakers Tell NJ Judges
• KaloBios Vows No Predatory Drug Pricing After Bankruptcy
• PE-Backed AdvancePierre Leads 3 New Filings With $100M IPO
• Endo, Impax Move To Trim Opana Pay-For-Delay MDL
• The Role Of Section 271(g) In The Wake Of ClearCorrect
• Watch Out: SEC Is Watching Your Dealings With Regulators
• Recovery From Q1 IPO Slump Could Take Years
• Abbott Can't Escape Punitive Damage Claim In Depakote Suit
• FDA Staff Not Convinced Of Clovis Cancer Drug Safety
• LD Vision Tells 10th Circ. Utah Is Blind To Lens Price Law
• Health Fraud Defense Attys Riding High As Wins Pile Up
• NJ Justices To Weigh Generic Reglan Preemption Claims
• Fed. Circ. Rules That Mayo Dooms Gene Detection Patent
• KaloBios Pharmaceuticals Files Renewed Ch. 11 Plan
• Health Hires: DLA Piper, King & Spalding Expand FDA Groups
• Mom Appeals Depakote Birth Defect Ruling To Sixth Circuit
• Fed. Circ. Won't Revive OxyContin Anti-Abuse Patent
• Nixon Peabody Can't Dodge Stock Fee Queries, Biotech Says
• Feds Say Flanax TM Ruling Bolsters Case Against Redskins
• Cold Spring RNA Patents Withstand AIA Challenge
• $200M Suture Antitrust Suit Nixed For Lack Of Market Power
• FDA Takes First Step To Remove Swine Drug From Market
• Proposed FDA Powdered Glove Ban: Effect On Device Makers
• Legal Delivery In The 'Gig Economy'
• Rising Star: Beasley Allen's Danielle Mason
• Ex-Access CEO Can't Now Claim Substance Abuse
• Adderall Buyers Seek Approval Of $15M Pay-For-Delay Deal
• DEA Mulling Whether To Reclassify Marijuana
• Theranos Boosts Board With MDs Amid Blood Test Spat
• FTC Wins Order Barring Japan Drug Co. From Generics Deals
• Fed. Circ. Sets New IP Trial Over J&J Expert's False Claims
• Rising Star: Ropes & Gray's Joy Liu
• Novartis, Feds Ordered To Hash Out Kickbacks Discovery
• Abbott Prevails In $219M Whistleblower FCA Trial
• PTAB Ruling Used New Arguments, Genzyme Tells Fed. Circ.
• J&J Must Face Cherokee Risperdal Suit In State Court
• Ex-Abbott Rep Says Profits Trumped Safety In $219M FCA Trial
• 6 Takeaways From Novartis FCPA Case
• Sanofi Can't Escape Junk Fax Suit After Campbell-Ewald
• Medtronic Wins FDA Approval For First Wireless Pacemaker
• Rising Star: Davis Polk's Sophia Hudson
• Ex-Morgan Stanley VP Gets 1 Day In Prison For Sanofi Scam
• Construction's $2.6B In Claims Easily Tops At AAA In 2015
• Texas Medical Equipment Co. Owners Charged With Fraud
• Nixed Pfizer Inversion Casts Uncertainty On Similar Deals
• FDA Calls Retroactive Exclusivity Unfair To Generics Makers
• BioPharma Services Provider InVentiv Files $100M IPO
• Antitrust Rule Of Reason Cases Tough To Try, Judges Say
• Wright Gets Damages Cut After First Hip Implant MDL Trial
• CVS, Rite Aid Hit Warner Chilcott With Loestrin Antitrust Suit
• Sweeping Medical Innovation Bill Nears Senate Vote
• 5 Best FDA Warning Letter Practices For Attorneys
• Pfizer, Allergan End $160B Merger After New Inversion Regs
• Pfizer Prevails In Zoloft Birth Defect MDL
• Excluded Evidence Could Revive Pa. Paxil Case On Appeal
• KaloBios Seeks End To Investor Suit To Clear Ch. 11 Plan
• Inversion Regs Cast Net Wider Than Pfizer-Allergan Deal
• Hospira Can't Shake Patent Row Over Generic Aloxi
• Wal-Mart's High-Cost Migraine Drug Misled, 9th Circ. Told
• Creative Solutions Needed To Pass TPP, Ex-USTR Official Says
• Ex-CEO Wants Stay In Former Oriole's Insider Trading Suit
• Sens. Introduce Bill To Protect Genetic Information
• Travelers Denied Win In Row Over Becton's $167M In Deals
• Deals Rumor Mill: Pfizer, Halliburton, Siemens
• Purdue Asks Fed. Circ. To Revive Anti-Abuse OxyContin IP
• Bayer Urges Fed Circ. To Reinstate Contraceptive Patent
• Eli Lilly Urges Justices To Rethink Patent-Eligibility Test
• FDA Backs Celltrion Biosimilar Of Janssen's Remicade
• FDA Warning Wire: Lice Lotion, Dirty Cheese, Workout Pills
• Health Network Wants Bellwethers Paused In Meningitis MDL
• Rising Star: Kaye Scholer's Aaron Gardner
• FDA Panel Outlines Hub For Medical Device Data
• GSK, Teva Pick Up Steam In Lamictal Pay-For-Delay Cert Bid
• 2nd Circ. Eyes BMS $30M Suit Over Mylan's Sale Of AIDS Drug
• Cubist Turns To Supreme Court In Antibiotic Patent Case
• Drugmaker SIGA Wins Approval Of Ch. 11 Plan
• FTC Amicus Brief Highlights Post-Actavis Challenges
• Lay And Expert Testimony: Using Employee Witnesses
• Ex-MedImmune Exec Can't End SEC's Ban After Settlement
• IRS Can Collect From Supplement Co., Tax Court Says
• Feds Trim Pay Boost For Medicare Advantage In 2017
• Rising Star: Dechert's Tony Chan
• J&J Witness Tells Jury Fired Exec Pursued Her
• 9th Circ. Revives Trade-Dress Claim Over Medical Reports
• Foley Picks Up IP Partner From Hogan Lovells In Japan
• Jury Finds Tyco Not Liable In $60M Drug Heist Trial
• Suture To Take $200M Antitrust Suit Dismissal To 10th Circ.
• Zimmer Wants Sanctions For Axed Suit In Knee Implant MDL
• Boston Scientific Testing Surgical Mesh For Fake Parts: FDA
• Biosimilar Notice Rule Isn't Absolute, Apotex Tells Fed. Circ.
• GSK Scores Midtrial Dismissal Of Paxil Birth Defect Suit
• UC Prof Fudged Painkiller Data, Drugmaker Alleges
• Mexican Official: Not Much Wiggle Room On Biologics In TPP
• 7 Lessons I Learned As A Trial Lawyer On Jury Duty
• Say It Ain't So: Fed. Circ. Denies ClearCorrect Rehearing
• Girardi Keese Hoarding $4.4M In Atty Fees, Co-Counsel Says
• Shkreli Says No Direct Infringement Of Wu-Tang Album Art
• Abbott Can't Duck Depakote Failure-To-Warn Birth Defect Suit
• NAM Urges Justices To Take Up Lamictal Pay-For-Delay Case
• Life Sciences IPOs Edge 1 Firm Ahead Of Peers In Quiet March
• Abbott Whistleblower Blasts Directed Verdict Bid
• Diet Pill Maker, Snooki Can't Ax Weight Loss False Ad Suit
• Rising Star: Quinn Emanuel's Andrew Chalson
• FTC Wins Restrictions On Lifewatch's Telemarketing
• Silver Lake Investment Values Ancestry.com At $2.6B
• Universities Protest House Panel's Fetal Tissue Subpoenas
• The 2016 Rising Stars, By Firm
• Insurer Urges Denial Of Directed Verdict In $60M Heist Suit
• Viewing Recent Opioid Regulations In Context